DelveInsight’s, “Chronic Idiopathic Urticaria (CIU) - Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Idiopathic Urticaria (CIU) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Chronic Idiopathic Urticaria (CIU): Overview
Chronic Urticaria (CU) conventionally refers to recurrent wheals, on most days of the week, which occur for a period of ≥ six weeks. CU can be further divided into two different subtypes, namely, Chronic Idiopathic Urticaria (CIU) (also called chronic spontaneous urticaria) and chronic inducible urticaria (also called physical urticaria). In most patients, CU is a sporadic and self-limited disorder. Chronic spontaneous urticaria refers to chronic urticaria that has no specific cause or trigger. Weals are present on most days of the week for 6 weeks or more. Chronic spontaneous urticaria was previously referred to as Chronic Idiopathic Urticaria (CIU). This term is no longer used as many cases have an autoimmune basis.
"Chronic Idiopathic Urticaria (CIU) - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Idiopathic Urticaria (CIU) pipeline landscape is provided which includes the disease overview and Chronic Idiopathic Urticaria (CIU) treatment guidelines. The assessment part of the report embraces, in depth Chronic Idiopathic Urticaria (CIU) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Idiopathic Urticaria (CIU) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Idiopathic Urticaria (CIU) R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Idiopathic Urticaria (CIU).
This segment of the Chronic Idiopathic Urticaria (CIU) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Idiopathic Urticaria (CIU) Emerging Drugs
Ligelizumab: Novartis
Ligelizumab (QGE031) is a next generation monoclonal anti-immunoglobulin E (IgE) antibody. Ligelizumab is thought to work by blocking the IgE/FcεRI pathway, a key driver of the inflammatory process in CSU. Ligelizumab (QGE031) had received FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU). Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines
Dupilumab: Regeneron
It is a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits IL-4 and interleukin-13 (IL-13) signaling by specifically binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes. It is in phase III stage of development to treat Chronic Spontaneous Urticaria.
Tezepelumab: Amgen
Tezepelumab is an investigational, potential first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants and other environmental insults. Specifically, tezepelumab targets and blocks thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma
Further product details are provided in the report……..
This segment of the report provides insights about the different Chronic Idiopathic Urticaria (CIU) drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 20+ key companies which are developing the therapies for Chronic Idiopathic Urticaria (CIU). The companies which have their Chronic Idiopathic Urticaria (CIU) drug candidates in the most advanced stage, i.e. phase III include, Novartis.
DelveInsight’s report covers around 20+ products under different phases of clinical development like
Chronic Idiopathic Urticaria (CIU) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Idiopathic Urticaria (CIU) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Idiopathic Urticaria (CIU) drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Chronic Idiopathic Urticaria (CIU): Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Ligelizumab: Novartis
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Tezepelumab: Amgen
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
UCB8600: UCB Pharma
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Chronic Idiopathic Urticaria (CIU) Key Companies
Chronic Idiopathic Urticaria (CIU) Key Products
Chronic Idiopathic Urticaria (CIU)- Unmet Needs
Chronic Idiopathic Urticaria (CIU)- Market Drivers and Barriers
Chronic Idiopathic Urticaria (CIU)- Future Perspectives and Conclusion
Chronic Idiopathic Urticaria (CIU) Analyst Views
Chronic Idiopathic Urticaria (CIU) Key Companies
Appendix
List of Table
Table 1: Total Products for Chronic Idiopathic Urticaria (CIU)
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Chronic Idiopathic Urticaria (CIU)
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Novartis
• Regeneron
• Amgen
• AstraZeneca
• United BioPharma
• Celltrion
• Celldex Therapeutics
• CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
• Gilead Sciences
• Stero Biotechs Ltd.
• UCB Biopharma SRL
• GlaxoSmithKline
• UBP Greater China (Shanghai) Co., Ltd
• Genentech
• Kiniksa Pharmaceuticals, Ltd.
